Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study

Mona Kafka; Giulia Giannini; Nastasiia Artamonova; Hannes Neuwirt; Heidemarie Ofner; Gero Kramer; Thomas Bauernhofer; Ferdinand Luger; Thomas Höfner; Wolfgang Loidl; Hubert Griessner; Lukas Lusuardi; Antonia Bergmaier; Andreas Berger; Thomas Winder; Sarah A. Weiss; Severin Bauinger; Steffen Krause; Martin Drerup; Elmar Heinrich; Magdalena Schneider; Stephan Madersbacher; Sonia Vallet; Franz Stoiber; Sarah Laimer; Stephan Hruby; Gert Schachtner; Udo Nagele; Sebastian Lenart; Anton Ponholzer; Jacob Pfuner; Clemens Wiesinger; Christoph Kamhuber; Ecan Müldür; Jasmin Bektić; Wolfgang Horninger; Isabel Heidegger

doi:10.1016/j.clgc.2023.12.018

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Triplet therapy arrived in clinical practice primarily for synchronous high-volume mHSPC. Regardless of selected therapy regimen, treatment is highly effective and tolerable. Preferably therapy should be administered simultaneously, however if not possible, chemotherapy should be started first.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kafka et al. (2024) studied this question.

synapsesocial.com/papers/69d981f2387cf7069868462c https://doi.org/10.1016/j.clgc.2023.12.018

View Full Paper

Ask AI

Bookmark

Share

Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study

Ask about this paper

Abstract

Discussion

Cite This Study

Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading